Zerbaxa (ceftolozane;tazobactam)
- Region
- 🇪🇺 EU
- Active substance
- ceftolozane;tazobactam
- Company
- Merck Sharp & Dohme B.V.
- Status
- Authorised
- Therapeutic area
- Bacterial Infections
- CHMP opinion
- Thu 23 Jul 2015
- EU approval
- Fri 18 Sep 2015
- Application
- EMEA/H/C/003772
- ATC
- J01DI54
- Official record
- www.ema.europa.eu
Indication
Zerbaxa is indicated for the treatment of the following infections in adults: Complicated intra abdominal infections; Acute pyelonephritis; Complicated urinary tract infections; Hospital-acquired pneumonia (HAP), including ventilator associated pneumonia (VAP). Consideration should be given to official guidance on the appropriate use of antibacterial agents.
Regulatory milestones
No milestones recorded in the last year.
Follow Zerbaxa
Get VigiEye Daily: approvals, opinions, safety actions and PDUFA dates every morning.
Information from official EMA, FDA, Federal Register and SEC records. Dates marked company-announced come from the company's own SEC filing; dates marked estimate are calculated, not official. Not investment or medical advice; always confirm on the source.